Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleCARDIOVASCULAR

Mechanism of Myricetin Stimulation of Vascular L-type Ca2+ Current

Fabio Fusi, Giampietro Sgaragli and Simona Saponara
Journal of Pharmacology and Experimental Therapeutics May 2005, 313 (2) 790-797; DOI: https://doi.org/10.1124/jpet.104.080135
Fabio Fusi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Giampietro Sgaragli
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Simona Saponara
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

An in-depth analysis of the mechanism of the L-type Ca2+ current [ICa(L)] stimulation induced by myricetin was performed in rat tail artery myocytes using the whole-cell patch-clamp method. Myricetin increased ICa(L) in a frequency-, concentration-, and voltage-dependent manner. At holding potentials (Vh) of –50 and –90 mV, the pEC50 values were 4.9 ± 0.1 and 4.2 ± 0.1, respectively; the latter corresponded to the drug-apparent dissociation constant for resting channels, KR, of 67.6 μM. Myricetin shifted the maximum of the current-voltage relationship by 10 mV in the hyperpolarizing direction but did not modify the threshold for ICa(L) or the T-type Ca2+ current. The Ca2+ channel blockers nifedipine, verapamil, and diltiazem antagonized ICa(L) in the presence of myricetin. Myricetin increased the time to peak of ICa(L) in a voltage- and concentration-dependent manner. Washout reverted myricetin effect on both current kinetics and amplitude at Vh of –90 mV while reverting only current kinetics at Vh of –50 mV. At the latter Vh, myricetin shifted the voltage dependence of inactivation and activation curves to more negative potentials by 6.4 and 13.0 mV, respectively, in the mid-potential of the curves. At Vh of –90 mV, myricetin shifted, in a concentration-dependent manner, the voltage dependence of the inactivation curve to more negative potentials with an apparent dissociation constant for inactivated channels (KI) of 13.8 μM. Myricetin induced a frequency- and Vh-dependent block of ICa(L). In conclusion, myricetin behaves as an L-type Ca2+ channel agonist that stabilizes the channel in its inactivated state.

Footnotes

  • This work was supported by grants from the Università degli Studi di Siena (PAR 2002 and 2001 Young Researcher to S.S.) and a grant from the Tuscany Region (Carabiotech 2002).

  • doi:10.1124/jpet.104.080135.

  • ABBREVIATIONS: PSS, physiological salt solution; Bay K 8644, (S)-(–)-methyl-1,4-dihydro-2,6-dimethyl-3-nitro-4-(2-trifluoromethylphenyl)pyridine-5-carboxylate.

    • Received November 4, 2004.
    • Accepted January 20, 2005.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 376 (2)
Journal of Pharmacology and Experimental Therapeutics
Vol. 376, Issue 2
1 Feb 2021
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Mechanism of Myricetin Stimulation of Vascular L-type Ca2+ Current
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleCARDIOVASCULAR

Mechanism of Myricetin Stimulation of Vascular L-type Ca2+ Current

Fabio Fusi, Giampietro Sgaragli and Simona Saponara
Journal of Pharmacology and Experimental Therapeutics May 1, 2005, 313 (2) 790-797; DOI: https://doi.org/10.1124/jpet.104.080135

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Research ArticleCARDIOVASCULAR

Mechanism of Myricetin Stimulation of Vascular L-type Ca2+ Current

Fabio Fusi, Giampietro Sgaragli and Simona Saponara
Journal of Pharmacology and Experimental Therapeutics May 1, 2005, 313 (2) 790-797; DOI: https://doi.org/10.1124/jpet.104.080135
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Mast Cell Degranulation Enhances Big ET-1 Pressor Response
  • Chemotherapy and Diastolic Dysfunction
  • Therapeutic Potential of Pharmacological DDAH
Show more Cardiovascular

Similar Articles

  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2021 by the American Society for Pharmacology and Experimental Therapeutics